Prognostic impact of a 3‐MicroRNA signature in cytological samples of small cell lung cancer

Abstract

BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive neoplasm that accounts for approximately 10% to 15% of lung cancers. In most cases, the diagnosis relies on cytology and needs to be confirmed by immunohistochemistry. Although several genetic and molecular abnormalities have been recorded, molecular markers able to predict the prognosis are still lacking. MicroRNA (miRNA) signatures have been recently proposed as useful biomarkers in lung cancer because of their high stability during standard sample processing. METHODS: Cytological samples for 50 patients with SCLC were collected from primary tumors (n 5 25) and metastases (n 5 25) by means of fine-needle aspiration (FNA) or bronchial washing (BW); they were fixed in ethanol (FNA) or Duboscq-Brazil fluid (BW). The 3-miRNA panel expression (miR-192, miR-200c, and miR-205) was quantified with a TaqMan polymerase chain reaction miRNA assay and was compared with overall survival (OS) and clinicopathological data. RESULTS: All samples had sufficient RNA for the miRNA expression analysis to be performed, regardless of the sample source or the fixative medium. Patients with a low expression level of the 3-miRNA panel were associated with better OS in univariate (P 5 .032) and multivariate analyses (P 5 .022). Moreover, in the group of patients older than the mean age of our cohort (65.8 years), a significant OS advantage (P 5 .013) was seen for patients with a low expression level of the 3-miRNA panel. CONCLUSIONS: A specific 3-miRNA signature is potentially useful for predicting survival for patients with SCLC, and it may be feasible with cytological samples taken during stand-

Prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio in small cell lung cancer: A retrospective analysis

“…The risk of disease progression in the low HRR group was 2.112 times as that in the high HRR group (95% CI, 1.195–3.733; P = 0.01), and the risk of death was 3.782 times as that in the high HRR group (95% CI, 2.151–6.652; P < 0.001). Compared with other peripheral blood indicators that can predict the prognosis of SCLC, such as circulating tumor cells and micro‐RNA, HRR can be determined using routine CBC, which is inexpensive and easy to perform. Thus, the economic burden on patients is reduced to some extent, and clinical practice becomes more convenient.…”

Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms

“…from primary tumors and 25 samples from lymph node metastases) (Mancuso et al 2016). These miRNAs were selected because the respective target genes are frequently altered in SCLC.…”

Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs

“…Low expression level of miR-7 was significantly associated with drug responsiveness and OS in 44 patients with SCLC53 . More recently, cytological samples from 50 patients with SCLC were analysed for the expression of a 3-miRNA panel (miR-192, miR-200c, and miR-205) and a better OS was described for patients with a low expression level of the 3-miRNA panel54 . Lee et al evaluated the expression pattern of three miRNAs (miR-21, miR-155 and miR let-7a) in a series of 63 lung NETs.…”